Search This Blog

Thursday, September 29, 2022

NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 M

 NIAID Agreement to Advance Development of Epetraborole for Acute Systemic Melioidosis

  • Non-dilutive funding will drive synergies with existing epetraborole development program for NTM lung disease

  • Award leverages AN2 Therapeutics expertise and commitment to address urgent unmet global health needs

  • Work could help address U.S. biothreat pathogen

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)